GlaxoSmithKline signed a global exclusive license with China’s Frontier Biotechnologies for two siRNA candidates in immunology, paying $40 million up front and up to $963 million in milestones. One program is already at the IND stage; the other is preclinical. GSK will develop, manufacture and commercialize the assets worldwide while Frontier continues early development in China. GSK framed the deal as a platform play to strengthen its immunology pipeline and kidney‑disease focus; Frontier’s leadership said the agreement validates its R&D capabilities and supports international collaboration and commercialization pathways.